lefradafiban

Gp IIb/IIIa receptor antagonists are potent antiplatelet agents since they block the final pathway in platelet aggregation… Expand

A key role has been established for platelet activation and thrombus formation in the pathogenesis of acute coronary syndromes… Expand

OBJECTIVE Lefradafiban is the orally active prodrug of fradafiban, a glycoprotein IIb/IIIa receptor antagonist. The present phase… Expand

AIMS Fibrinogen receptor antagonists show a close relationship between plasma concentrations and inhibitory effect. Optimal… Expand

AIMS Oral glycoprotein IIb/IIIa inhibitors might enhance the early benefit of an intravenous agent and prevent subsequent cardiac… Expand

We have used a whole blood single-platelet counting assay (WB-SPC) that is sensitive to microaggregation for monitoring GPIIb… Expand

 

Summary Since platelet aggregation is dependent on the presence of functional GP IIb/IIIa receptors and since this receptor is… Expand

Recent studies of the effects of glycoprotein (GP) IIb/IIIa receptor antagonists on the clinical outcomes of patients with… Expand

BACKGROUND Clinical trials have demonstrated that platelet glycoprotein (GP) IIb/IIIa antagonists effectively prevent acute… Expand